From 15f5cc35e86f412728337a6b243656d8700621d5 Mon Sep 17 00:00:00 2001 From: borja Date: Thu, 31 Oct 2024 13:01:51 +0100 Subject: [PATCH] Auto saved by Logseq --- journals/2024_10_31.md | 3 ++- 1 file changed, 2 insertions(+), 1 deletion(-) diff --git a/journals/2024_10_31.md b/journals/2024_10_31.md index afb1ce10..1f10ebaa 100644 --- a/journals/2024_10_31.md +++ b/journals/2024_10_31.md @@ -19,7 +19,8 @@ - Stella agrees. Its more showing the path that it takes for new products to be able to be sent out to the masses than the process where is now. - Demonstrating that doing the pivotal trial and submit to regulatory agencies doesn't mean inclusion in programs. - I got in touch with EDCTP authorities to highlight that PZQ and moxi and fdc are all edctp invesments. They are very happy about it. - - Maurice: what i gather is present the clinical findings and highlight what the next steps are. Im' + - Maurice: what i gather is present the clinical findings and highlight what the next steps are. Im not in the access program. I just know generalically. They're trying to get aproval in Kenya. I cannot give many specifics but yes about the pivotal trials. The panel can take it from there. + - Stella: Those iinvolved in the access will be in the audience. Look at the path from inception to - ### Decisiones - - CANCELED 17:00 - 17:30: Pre-Symposium meeting